Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Child cancer and birth defects: hidden genetic clues?

NCT ID NCT01915797

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study collected information from nearly 1,000 children who had both cancer and developmental abnormalities like birth defects or growth issues. The goal was to find new genetic syndromes that make children more likely to develop cancer. Researchers analyzed blood and tumor samples to understand the underlying causes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify new genetic syndromes that make children more likely to develop cancer, leading to earlier detection and better monitoring.
What could go wrong
This is an observational study, not a treatment trial. It may not directly benefit participants, and identifying new syndromes does not guarantee improved outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

998 people

The number who actually took part.

Started

Jun 2013

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient having developed a cancerous pathology and presenting one or several anomalies of the development.

Ages

0 days to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : \- Patient who developed before the age of 18 years a solid tumour or a malignant or borderline hemopathy. AND * Presenting one or several abnormality (ies) of the development provided it is not related to the treatment and\\or to the disease among: * organ malformation, familial or not * neuro-sensory deficit, familial or not * delay of psychomotor acquisitions * epilepsy (not as a sequelae of the tumour) * disorder of growth and\\or weight and\\or of the cranial perimeter * congenital, sporadic and\\or familial endocrine or metabolic disease * dysmorphy * Informed consent of patient and parents to this study OR * tumour predisposition syndrome or developmental abnormality in a familial context, the molecular basis might have been already identified or not Exclusion Criteria: * absence of malignancy in the index case * lack of developmental anomalies in the index case or in a related first degree * abnormal development recognized as acquired (traumatic, toxic, infectious, perinatal…) * age \> 18 years at diagnosis of the tumor * Lack of informed consent of the legal representatives The familial aggregations of cancer without developmental disease are not included in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant hemopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

childhood neoplasm hematopoietic and lymphoid cell neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tumor and abnormalities of the development

Contacts and locations

Locations

  • Hôpital Necker Enfants Malades

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.